Spero Therapeutics reported earnings of -$ 0.76 per SPRO share on Nov 12, 2026, beating analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.47 |
| Earnings Per Share (Surprise) | -$ 0.76 (-$ 0.29) |
| Last Year's EPS | $ 0.03 |
| EPS YoY Change |
Out of the last 41 earnings reporting periods, Spero Therapeutics beat analysts’ expectations 24 times and fell short of expectations 12 time(s). Spero Therapeutics reported earnings per share of -$ 0.76 in the last report falling to reach an estimated EPS of -$ 0.47 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.47 | -$ 0.76 | -$ 0.13 | |
| Aug 12, 2026 | -$ 0.17 | -$ 0.16 | -$ 0.03 | |
| May 13, 2026 | -$ 0.18 | -$ 0.13 | -$ 0.25 | |
| Mar 26, 2026 | -$ 0.20 | $ 0.53 | -$ 0.38 | |
| Nov 13, 2025 | -$ 0.25 | -$ 0.13 | -$ 0.32 | |
| Aug 12, 2025 | -$ 0.38 | -$ 0.03 | -$ 0.33 | |
| May 13, 2025 | -$ 0.55 | -$ 0.25 | -$ 0.24 | |
| Mar 27, 2025 | -$ 0.35 | -$ 0.38 | $ 0.96 | |
| Nov 14, 2024 | -$ 0.27 | -$ 0.32 | $ 0.02 | |
| Aug 5, 2024 | -$ 0.35 | -$ 0.33 | -$ 0.23 | |
| May 15, 2024 | -$ 0.07 | -$ 0.24 | -$ 0.25 | |
| Mar 13, 2024 | -$ 0.10 | $ 0.96 | $ 0.55 | |
| Nov 13, 2023 | -$ 0.15 | $ 0.02 | -$ 0.33 | |
| Aug 10, 2023 | -$ 0.29 | -$ 0.23 | -$ 0.87 | |
| May 11, 2023 | -$ 0.35 | -$ 0.25 | -$ 1.01 | |
| Mar 30, 2023 | $ 0.04333 | $ 0.55 | -$ 0.90 | |
| Nov 14, 2022 | -$ 0.34 | -$ 0.33 | -$ 0.70 | |
| Aug 10, 2022 | -$ 0.88 | -$ 0.87 | -$ 0.63 | |
| May 16, 2022 | -$ 0.87 | -$ 1.01 | -$ 0.66 | |
| Mar 31, 2022 | -$ 0.80 | -$ 0.90 | -$ 0.68 |
Spero Therapeutics’s stock was trading at $ 1.02 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, SPRO’s price decreased to $ 0.9999 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.76 | $ 1.02 | $ 0.9999 | |
| Aug 12, 2026 | -$ 0.16 | $ 1.23 | $ 1.24 | |
| May 13, 2026 | -$ 0.13 | $ 2.54 | $ 2.76 | |
| Mar 26, 2026 | $ 0.53 | $ 2.41 | $ 2.33 | |
| Nov 13, 2025 | -$ 0.13 | $ 2.66 | $ 2.41 | |
| Aug 12, 2025 | -$ 0.03 | $ 2.20 | $ 1.94 | |
| May 13, 2025 | -$ 0.25 | $ 0.61 | $ 0.6501 | |
| Mar 27, 2025 | -$ 0.38 | $ 0.89 | $ 0.7665 | |
| Nov 14, 2024 | -$ 0.32 | $ 1.31 | $ 1.18 | |
| Aug 5, 2024 | -$ 0.33 | $ 1.31 | $ 1.27 | |
| May 15, 2024 | -$ 0.24 | $ 1.60 | $ 1.57 | |
| Mar 13, 2024 | $ 0.96 | $ 1.66 | $ 1.74 | |
| Nov 13, 2023 | $ 0.02 | $ 1.11 | $ 1.09 | |
| Aug 10, 2023 | -$ 0.23 | $ 1.45 | $ 1.40 | |
| May 11, 2023 | -$ 0.25 | $ 1.90 | $ 1.85 | |
| Mar 30, 2023 | $ 0.55 | $ 1.45 | $ 1.45 | |
| Nov 14, 2022 | -$ 0.33 | $ 2.00 | $ 1.88 | |
| Aug 10, 2022 | -$ 0.87 | $ 0.776 | $ 0.779 | |
| May 16, 2022 | -$ 1.01 | $ 1.71 | $ 1.65 | |
| Mar 31, 2022 | -$ 0.90 | $ 8.61 | $ 7.11 |
Spero Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Spero Therapeutics missed analysts’ expectations during the last earnings period by
